Radiation dosimetry results for zevalin radioimmunotherapy of rituximab-refractory non-hodgkin lymphoma-Reference-Cited by-同舟云学术

Radiation dosimetry results for zevalin radioimmunotherapy of rituximab-refractory non-hodgkin lymphoma

Published:2002-02-12 Issue:S4 Volume:94 Page:1349-1357
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Wiseman Gregory A.,Leigh Bryan,Erwin William D.,Lamonica Dominick,Kornmehl Ellen,Spies Stewart M.,Silverman Daniel H. S.,Witzig Thomas E.,Sparks Richard B.,White Christine A.

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference19 articles.

1. Phase I/II 90 Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma

2. Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin™ radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma

3. Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation

4. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20

Cited by 73 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical Applications of Immuno-PET in Lymphoma: A Systematic Review;Cancers;2022-07-18

2. 89Zr-PET imaging to predict tumor uptake of 177Lu-NNV003 anti-CD37 radioimmunotherapy in mouse models of B cell lymphoma;Scientific Reports;2022-04-15

3. Simulated Radiation Dosimetry Models After Intraventricular and Intralumbar Injection of Radiopharmaceuticals;Radiopharmaceuticals in the Management of Leptomeningeal Metastasis;2022

4. Dosimetry in Clinical Radiopharmaceutical Therapy of Cancer: Practicality Versus Perfection in Current Practice;Journal of Nuclear Medicine;2021-12

5. ICRU REPORT 96, Dosimetry-Guided Radiopharmaceutical Therapy;Journal of the ICRU;2021-12